uniQure reported Q1 2026 financial results and progress on its gene therapy pipeline, notably AMT-130 for Huntington’s disease. The company plans a UK Marketing Authorization Application submission in Q3 2026 after positive MHRA feedback and will discuss new clinical trial designs with the FDA in Q2. Clinical updates for AMT-260 epilepsy and AMT-130 four-year data are expected later in 2026. uniQure holds $586.6 million cash, funding operations into late 2029, supporting ongoing development and regulatory efforts.
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
Heathrow Finance PLC announced a €350 million offering of 4-year senior secured notes with a stabilization period starting July 2, 2026, and ending by August 7, 2026. BNP Paribas and other major banks will manage the stabilization to support the bond...
Polibeli Group Ltd. has signed a non-binding Memorandum of Understanding with AUTHAIKAM COMPANY LIMITED to jointly evaluate a potential 100 MW AI computing center project in Thailand. The collaboration involves preliminary assessments such as site vi...
